CDX2 and cancer: In the etiology of these cancers, as CIMP phenotype is an early event occurring before the oncogenic BRAF mutation51, our findings here suggest that downregulation of CDX2 in the context of CIMP-H phenotype might create an early permissive state allowing BRAF mutation to exert its oncogenic effects.